
Oculis Holding AG (NASDAQ:OCS – Free Report) – HC Wainwright reduced their FY2026 EPS estimates for shares of Oculis in a research report issued to clients and investors on Tuesday, November 17th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($2.27) for the year, down from their previous estimate of ($1.63). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.65) EPS, Q1 2027 earnings at ($0.66) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.68) EPS and FY2027 earnings at ($2.69) EPS.
Oculis (NASDAQ:OCS – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.10. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.26 million. Oculis had a negative return on equity of 39.24% and a negative net margin of 8,613.92%.
A number of other analysts also recently weighed in on OCS. JPMorgan Chase & Co. reduced their target price on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Guggenheim lowered their target price on Oculis to $40.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and an average price target of $38.57.
Check Out Our Latest Stock Analysis on OCS
Oculis Price Performance
OCS stock opened at $7.39 on Thursday. The firm has a 50-day moving average of $8.48 and a 200 day moving average of $17.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.41 and a quick ratio of 10.41. The company has a market cap of $428.47 million, a P/E ratio of -4.32 and a beta of 0.67. Oculis has a 1 year low of $6.78 and a 1 year high of $34.47.
Hedge Funds Weigh In On Oculis
Several institutional investors have recently bought and sold shares of the stock. Aquatic Capital Management LLC bought a new stake in Oculis in the 3rd quarter valued at $134,000. Goldman Sachs Group Inc. boosted its holdings in shares of Oculis by 103.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 141,688 shares of the company’s stock valued at $1,323,000 after purchasing an additional 72,186 shares during the last quarter. Checkpoint Capital L.P. bought a new position in shares of Oculis during the 3rd quarter valued at about $929,000. Alps Advisors Inc. boosted its holdings in shares of Oculis by 40.7% during the 3rd quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock valued at $762,000 after purchasing an additional 23,600 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Oculis during the third quarter valued at about $74,000. 22.30% of the stock is owned by hedge funds and other institutional investors.
About Oculis
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
Read More
- Five stocks we like better than Oculis
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
